ATE399323T1 - Verfahren zur bestimmung von amyloidogenen proteinen - Google Patents
Verfahren zur bestimmung von amyloidogenen proteinenInfo
- Publication number
- ATE399323T1 ATE399323T1 AT00980905T AT00980905T ATE399323T1 AT E399323 T1 ATE399323 T1 AT E399323T1 AT 00980905 T AT00980905 T AT 00980905T AT 00980905 T AT00980905 T AT 00980905T AT E399323 T1 ATE399323 T1 AT E399323T1
- Authority
- AT
- Austria
- Prior art keywords
- aggregation
- assay
- determining
- amyloid
- peptide
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 102000009091 Amyloidogenic Proteins Human genes 0.000 title 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 title 1
- 230000002776 aggregation Effects 0.000 abstract 4
- 238000004220 aggregation Methods 0.000 abstract 4
- 238000003556 assay Methods 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000004847 absorption spectroscopy Methods 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 238000002983 circular dichroism Methods 0.000 abstract 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 abstract 1
- 230000035557 fibrillogenesis Effects 0.000 abstract 1
- 238000001506 fluorescence spectroscopy Methods 0.000 abstract 1
- 238000010874 in vitro model Methods 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/474,970 US6399314B1 (en) | 1999-12-29 | 1999-12-29 | Methods of detection of amyloidogenic proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE399323T1 true ATE399323T1 (de) | 2008-07-15 |
Family
ID=23885720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00980905T ATE399323T1 (de) | 1999-12-29 | 2000-12-01 | Verfahren zur bestimmung von amyloidogenen proteinen |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6399314B1 (de) |
| EP (1) | EP1242822B1 (de) |
| JP (1) | JP2003519383A (de) |
| KR (1) | KR20020070470A (de) |
| CN (1) | CN1211661C (de) |
| AT (1) | ATE399323T1 (de) |
| AU (1) | AU774377B2 (de) |
| BR (1) | BR0016883A (de) |
| CA (1) | CA2395789C (de) |
| DE (1) | DE60039310D1 (de) |
| DK (1) | DK1242822T3 (de) |
| EA (1) | EA005582B1 (de) |
| ES (1) | ES2309003T3 (de) |
| HK (1) | HK1046550B (de) |
| IL (2) | IL150080A0 (de) |
| MX (1) | MXPA02006362A (de) |
| NO (1) | NO20023163L (de) |
| NZ (1) | NZ519612A (de) |
| PL (1) | PL356813A1 (de) |
| PT (1) | PT1242822E (de) |
| WO (1) | WO2001050134A2 (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| DE19923811C1 (de) * | 1999-05-20 | 2000-12-07 | Robert Koch Inst | Verfahren zur Diagnose TSE-induzierter Veränderungen in Geweben mittels Infrarotspektroskopie |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| US6689753B1 (en) * | 1999-11-05 | 2004-02-10 | Axonyx, Inc. | β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide |
| JP4853936B2 (ja) | 2000-08-21 | 2012-01-11 | ザ ジェネラル ホスピタル コーポレイション | 神経変性状態の診断方法 |
| PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| WO2003018068A1 (en) * | 2001-04-27 | 2003-03-06 | The General Hospital Corporation | Ocular diagnosis of alzheimer's disease |
| US20050026165A1 (en) * | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
| AU2002320045B2 (en) * | 2001-05-31 | 2008-05-08 | Adlyfe, Inc. | Misfolded protein sensor method |
| WO2003059387A2 (en) * | 2001-12-21 | 2003-07-24 | Ilex Oncology, Inc. | Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis |
| MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| EP1380290A1 (de) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-Beta-Strukturweg und seine therapeutische Relevanz |
| US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| US20050048539A1 (en) * | 2003-06-13 | 2005-03-03 | The General Hospital Corporation | Methods to monitor molecule conformation and molecule/molecule proximity |
| SE0401219D0 (sv) * | 2004-05-10 | 2004-05-10 | Biochromix Ab | Metoder för detektera konformationsförändringar eller aggregering hos proteiner med hjälp av konjugerade polyelektrolyter |
| US20060057671A1 (en) * | 2004-09-10 | 2006-03-16 | Orser Cindy S | Immobilized probes and methods of detecting conformationally altered prion proteins |
| JP2008523815A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
| US7625560B2 (en) * | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| EP1838349A1 (de) * | 2004-12-15 | 2007-10-03 | Neuralab, Ltd. | Amyloid-beta-antikörper zur verbesserung der kognition |
| JP4568840B2 (ja) * | 2004-12-28 | 2010-10-27 | 国立大学法人金沢大学 | アルツハイマー病の検査方法 |
| WO2006069697A1 (en) * | 2004-12-30 | 2006-07-06 | F. Hoffmann-La Roche Ag | Colorimetrically assessing peptide characteristics |
| ATE528649T1 (de) * | 2005-02-15 | 2011-10-15 | Adlyfe Inc | Verfahren zum nachweis falsch gefalteter proteine und prionen |
| US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
| US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
| EP1906995A2 (de) * | 2005-07-13 | 2008-04-09 | Crossbeta Biosciences B.V. | Adjuvation durch kreuzstruktur |
| US20070015133A1 (en) * | 2005-07-13 | 2007-01-18 | Umc Utrecht Holding B.V. | Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein |
| AU2006267176A1 (en) * | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | Cross-beta structure binding compounds |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8673579B2 (en) * | 2006-07-28 | 2014-03-18 | Adlyfe, Inc. | Peptide probes for diagnostics and therapeutics |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2058000A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung |
| EP2058001A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Steigerung der Immunogenizität von Antigenen |
| US20100021390A1 (en) * | 2008-03-17 | 2010-01-28 | The Research Foundation Of State University Of New York | Fluorescent Analogs Of The Islet Amyloid Polypeptide |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| RU2509155C1 (ru) * | 2012-10-25 | 2014-03-10 | Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук | Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии |
| GB201303507D0 (en) * | 2013-02-27 | 2013-04-10 | Hollfelder Florian | Assays |
| US9588129B2 (en) * | 2013-03-15 | 2017-03-07 | Amira Medical Technologies Inc. | Methods for analyzing blood to detect diseases associated with abnormal protein aggregation |
| CN104803993B (zh) * | 2015-03-01 | 2017-11-03 | 四川大学 | 一种具有Aβ亲和力的荧光化合物及其用途 |
| CN105651752B (zh) * | 2016-02-26 | 2019-04-12 | 国家纳米科学中心 | 淀粉样蛋白的检测方法 |
| CN105717182B (zh) * | 2016-03-10 | 2018-05-11 | 中南大学 | 一种用于同步检测淀粉样多肽单体和聚集体的生物传感器及其构建方法和应用 |
| US11536731B2 (en) | 2017-01-23 | 2022-12-27 | Rensselaer Polytechnic Institute | Systems and methods for binding amyloid fibrils using fluorescent protein |
| CN108489941B (zh) * | 2018-01-31 | 2021-07-27 | 吉林大学 | 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用 |
| CN112912732A (zh) * | 2018-08-03 | 2021-06-04 | 香港大学 | 用于淀粉样蛋白原纤维、淀粉样蛋白斑块、rna和核仁的检测和成像的组合物和方法 |
| CA3120066A1 (en) | 2018-11-14 | 2020-05-22 | University Of Kentucky Research Foundation | Diagnosis of diabetes by detecting aggregated amylin in erythrocytes |
| CN111504957B (zh) * | 2019-01-31 | 2021-12-03 | 吉林大学 | 一种维多利亚蓝b及其衍生物在制备异构化蛋白的探针或抑制剂中的应用 |
| KR102258048B1 (ko) * | 2019-05-30 | 2021-05-31 | 주식회사 캔티스 | 아밀로이드 베타 올리고머의 검출 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2013396A1 (en) * | 1989-04-05 | 1990-10-05 | Dennis J. Selkoe | Diagnostic method for alzheimer's disease: examination of non-neural tissue |
| US5276059A (en) | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
| AU6728396A (en) | 1995-08-17 | 1997-03-12 | Ontario Cancer Institute, The | Protein fibril assembly assay |
| JPH0995444A (ja) * | 1995-10-02 | 1997-04-08 | Teijin Ltd | アミロイド蛋白凝集阻害剤 |
| CA2301142A1 (en) | 1997-08-14 | 1999-02-25 | The Regents Of The University Of California | Fluorescent amyloid a.beta. peptides and uses thereof |
| WO1999045947A1 (en) * | 1998-03-13 | 1999-09-16 | University Of Washington | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases |
-
1999
- 1999-12-29 US US09/474,970 patent/US6399314B1/en not_active Expired - Fee Related
-
2000
- 2000-12-01 HK HK02108122.2A patent/HK1046550B/en not_active IP Right Cessation
- 2000-12-01 EP EP00980905A patent/EP1242822B1/de not_active Expired - Lifetime
- 2000-12-01 BR BR0016883-1A patent/BR0016883A/pt not_active Application Discontinuation
- 2000-12-01 MX MXPA02006362A patent/MXPA02006362A/es active IP Right Grant
- 2000-12-01 ES ES00980905T patent/ES2309003T3/es not_active Expired - Lifetime
- 2000-12-01 PT PT00980905T patent/PT1242822E/pt unknown
- 2000-12-01 JP JP2001550033A patent/JP2003519383A/ja active Pending
- 2000-12-01 IL IL15008000A patent/IL150080A0/xx active IP Right Grant
- 2000-12-01 DE DE60039310T patent/DE60039310D1/de not_active Expired - Lifetime
- 2000-12-01 AU AU18103/01A patent/AU774377B2/en not_active Ceased
- 2000-12-01 KR KR1020027008505A patent/KR20020070470A/ko not_active Ceased
- 2000-12-01 PL PL00356813A patent/PL356813A1/xx not_active Application Discontinuation
- 2000-12-01 CN CNB008178658A patent/CN1211661C/zh not_active Expired - Fee Related
- 2000-12-01 WO PCT/US2000/032693 patent/WO2001050134A2/en not_active Ceased
- 2000-12-01 EA EA200200722A patent/EA005582B1/ru not_active IP Right Cessation
- 2000-12-01 NZ NZ519612A patent/NZ519612A/en unknown
- 2000-12-01 CA CA2395789A patent/CA2395789C/en not_active Expired - Fee Related
- 2000-12-01 AT AT00980905T patent/ATE399323T1/de not_active IP Right Cessation
- 2000-12-01 DK DK00980905T patent/DK1242822T3/da active
-
2002
- 2002-06-06 IL IL150080A patent/IL150080A/en not_active IP Right Cessation
- 2002-06-28 NO NO20023163A patent/NO20023163L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ519612A (en) | 2004-04-30 |
| HK1046550B (en) | 2008-12-19 |
| IL150080A (en) | 2009-02-11 |
| CN1211661C (zh) | 2005-07-20 |
| JP2003519383A (ja) | 2003-06-17 |
| NO20023163L (no) | 2002-08-27 |
| CA2395789C (en) | 2010-03-30 |
| HK1046550A1 (en) | 2003-01-17 |
| WO2001050134A2 (en) | 2001-07-12 |
| BR0016883A (pt) | 2002-10-01 |
| AU1810301A (en) | 2001-07-16 |
| MXPA02006362A (es) | 2002-11-29 |
| WO2001050134A3 (en) | 2002-06-27 |
| DK1242822T3 (da) | 2008-09-29 |
| AU774377B2 (en) | 2004-06-24 |
| EP1242822B1 (de) | 2008-06-25 |
| DE60039310D1 (de) | 2008-08-07 |
| EA200200722A1 (ru) | 2002-12-26 |
| EP1242822A2 (de) | 2002-09-25 |
| US6399314B1 (en) | 2002-06-04 |
| PL356813A1 (en) | 2004-07-12 |
| IL150080A0 (en) | 2002-12-01 |
| CN1415074A (zh) | 2003-04-30 |
| EA005582B1 (ru) | 2005-04-28 |
| CA2395789A1 (en) | 2001-07-12 |
| ES2309003T3 (es) | 2008-12-16 |
| KR20020070470A (ko) | 2002-09-09 |
| NO20023163D0 (no) | 2002-06-28 |
| PT1242822E (pt) | 2008-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60039310D1 (de) | Verfahren zur bestimmung von amyloidogenen proteinen | |
| DK0679251T3 (da) | Fremgangsmåde og apparat til vurdering af biopolymerers fitness | |
| DE59903915D1 (de) | Verfahren zur frühen diagnose von carcinomen | |
| ATE509119T1 (de) | Verfahren zum testen von glykosyliertem protein | |
| ATE494393T1 (de) | Testverfahren für nukleinsäuren mittels fluoreszenz | |
| DE59914830D1 (de) | Verfahren und testbesteck zur beurteilung der oxid messung ihrer antiradikalen aktivität | |
| Strucksberg et al. | Proteasomal activity in skeletal muscle: a matter of assay design, muscle type, and age | |
| ATE514951T1 (de) | Verfahren zur prüfung eines mehrkanaligen elements zur blutanalyse | |
| Zinellu et al. | Highly sensitive simultaneous detection of cultured cellular thiols by laser induced fluorescence‐capillary electrophoresis | |
| DE50010710D1 (de) | Verfahren zur bestimmung von substanzen mittels der evaneszenzfeldmethode | |
| EA199800493A1 (ru) | Анализ крови на соотношение активности фактора v для оценки вероятности заболевания тромбоэмболией | |
| Gołuński et al. | Modulation of acridine mutagen ICR191 intercalation to DNA by methylxanthines—analysis with mathematical models | |
| DE60229303D1 (de) | Bioäquivalenztest für eisenhaltige formulierungen | |
| DE50212790D1 (de) | Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper | |
| RU2013158623A (ru) | Способ идентификации лигандов для белков, агрегированных в бета-листы | |
| ATE534037T1 (de) | Verwendung des proteins asc als marker für brustkrebs | |
| ATE466285T1 (de) | Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers | |
| DE60324820D1 (de) | Verfahren zum testen des oxidiertes-ldl-beta-2-glycoprotein-i-komplexes in vivo | |
| DE602005015627D1 (de) | Verfahren zur messung von proinsulin und c-peptid sowie kit dafür | |
| Falamas et al. | Monitoring the RNA distribution in human embryonic stem cells using Raman micro-spectroscopy and fluorescence imaging | |
| ATE204079T1 (de) | Verfahren zur spektralanalyse von inhomogenen proben | |
| DE50213297D1 (de) | Verfahren und mittel zur bestimmung von gesamtsäure | |
| SU1746960A1 (ru) | Способ определени степени зрелости икры рыб | |
| ATE317454T1 (de) | Verfahren zur aktivitätsbestimmung einer substanz mittels eines funktionellen in vitro tests | |
| FR2846009B1 (fr) | Criblage de molecules a activite anti-prion:kits, methodes et molecules criblees |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1242822 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |